论文部分内容阅读
目的观察阿米卡星联合左氧氟沙星治疗耐多药肺结核的临床效果。方法将180例耐多药肺结核患者随机分为观察组和对照组各90例。观察组进行阿米卡星联合左氧氟沙星治疗;对照组给予乙胺丁醇联合链霉素治疗。观察2组患者的治疗效果与不良反应发生率。结果观察组总有效率为100.00%高于对照组的78.89%,不良反应发生率为3.3%低于对照组的11.1%,差异均有统计学意义(P<0.05)。结论阿米卡星联合左氧氟沙星治疗耐多药肺结核患者治疗效果显著,且不良发应的发生率较低,值得在临床上广泛推广。
Objective To observe the clinical effect of amikacin combined with levofloxacin in the treatment of multi-drug resistant pulmonary tuberculosis. Methods 180 cases of MDR-TB patients were randomly divided into observation group and control group of 90 cases. The observation group was treated with amikacin and levofloxacin. The control group was treated with ethambutol and streptomycin. The treatment effect and incidence of adverse reactions in two groups were observed. Results The total effective rate was 100.00% in the observation group, 78.89% in the control group and 3.3% in the adverse reaction group, which was lower than 11.1% in the control group (P <0.05). Conclusion Amikacin combined with levofloxacin in the treatment of multidrug-resistant pulmonary tuberculosis patients with significant effect, and the incidence of adverse reactions is low, it is widely used in clinical practice.